Avid Bioservices unveils latest downstream processing suite

Avid Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), has officially opened the second downstream processing suite within the company’s existing Myford North facility in Tustin, CA.

This new addition was constructed as the first phase of the company’s two-part Myford facility expansion, a project that Avid officials believe will result in a total revenue generating capacity of up to approximately $270 million for the mammalian cell business annually.

“… With this milestone, we now have two fully operational downstream processing suites within Myford North, significantly increasing the facility’s capacity and revenue-generating capability,” says Nick Green, president and CEO of Avid Bioservices. “We’re excited that we will begin work on our first customer project in this newly operational suite in the coming month and look forward to delivering those customers the same reliable, high-quality services that our customers have come to expect from Avid.”

The second phase of the CDMO's Myford facility expansion, in which construction is underway, is meant to increase capacity by designing a second manufacturing train, one that features both upstream and downstream processing suites within Myford South.

The company is also in the process of building a 53,000 square-foot viral vector development and current good manufacturing practice (cGMP) manufacturing facility in Costa Mesa, CA, which is about five miles from Avid’s Tustin location.